Abstract
B cells play a central role in the pathogenesis of SLE. Not only do they make autoantibodies, but they can provide immunoregulatory controls of T cells, dendritic cells, and other B cells, in part through cytokine production. The availability of a chimeric monoclonal antibody that targets B cells has made it possible to treat SLE by B-cell depletion. Rituximab binds to the B-cell specific antigen CD20, and depletes B cells from the peripheral blood and lymphoid tissues. A growing number of anecdotal series and case reports suggest that rituximab may provide clinical benefit in SLE with acceptable toxicity, although the variability in responses of individual patients is not yet fully understood. Two large ongoing randomized controlled trials will determine the efficacy of rituximab in SLE, both renal and extra-renal, and will inform us better about the biology of the B cell in this disease and the effects of B-cell depletion.
Keywords: SLE, B cells, rituximab, CD20, chimeric monoclonal antibody
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: Targeting B Cells in SLE: The Experience with Rituximab Treatment (Anti-CD20)
Volume: 6 Issue: 4
Author(s): Robert Eisenberg
Affiliation:
Keywords: SLE, B cells, rituximab, CD20, chimeric monoclonal antibody
Abstract: B cells play a central role in the pathogenesis of SLE. Not only do they make autoantibodies, but they can provide immunoregulatory controls of T cells, dendritic cells, and other B cells, in part through cytokine production. The availability of a chimeric monoclonal antibody that targets B cells has made it possible to treat SLE by B-cell depletion. Rituximab binds to the B-cell specific antigen CD20, and depletes B cells from the peripheral blood and lymphoid tissues. A growing number of anecdotal series and case reports suggest that rituximab may provide clinical benefit in SLE with acceptable toxicity, although the variability in responses of individual patients is not yet fully understood. Two large ongoing randomized controlled trials will determine the efficacy of rituximab in SLE, both renal and extra-renal, and will inform us better about the biology of the B cell in this disease and the effects of B-cell depletion.
Export Options
About this article
Cite this article as:
Eisenberg Robert, Targeting B Cells in SLE: The Experience with Rituximab Treatment (Anti-CD20), Endocrine, Metabolic & Immune Disorders - Drug Targets 2006; 6 (4) . https://dx.doi.org/10.2174/187153006779025757
DOI https://dx.doi.org/10.2174/187153006779025757 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Vascularization of Engineered Tissues: Approaches to Promote Angiogenesis in Biomaterials
Current Topics in Medicinal Chemistry Increasing Sensitivity to Radiotherapy and Chemotherapy by Using Novel Biological Agents that Alter the Tumor Microenvironment
Current Molecular Medicine Triphala in Prevention of Dental Caries and as an Antimicrobial in Oral Cavity- A Review
Infectious Disorders - Drug Targets Use of Push-Pull Superfusion Technique for Identifying Neurotransmitters Involved in Brain Functions: Achievements and Perspectives
Current Neuropharmacology Anti - TNF Therapy for Crohns Disease
Current Pharmaceutical Design Metabolism and Mechanism of Human Cytochrome P450 Enzyme 1A2
Current Drug Metabolism Targeting Small Arteries of Hypertensive Status with Novel ATP-Sensitive Potassium Channel Openers&#
Current Vascular Pharmacology Flavonoids in Cancer Prevention
Anti-Cancer Agents in Medicinal Chemistry Pathophysiology, Diagnosis and Clinical Management of Hepatorenal Syndrome: From Classic to New Drugs
Current Vascular Pharmacology Pathophysiology of Blood-Brain Barrier in Brain Injury in Cold and Hot Environments: Novel Drug Targets for Neuroprotection
CNS & Neurological Disorders - Drug Targets Hypertension Impairs Cerebral Blood Flow in a Mouse Model for Alzheimer’s Disease
Current Alzheimer Research Potential Strategies for Minimizing Mechanism-Based Inhibition of Cytochrome P450 3A4
Current Pharmaceutical Design Adipose Tissue and Bone Marrow as Sources for Cell-based Therapeutic Angiogenesis in Ischemic Tissues: Biological Foundation and Clinical Prospects for Age-related Vascular Disease
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Cardiovascular Consequences of Weightlessness Promote Advances in Clinical and Trauma Care
Current Pharmaceutical Biotechnology Biochemical Markers of Renal Function
Current Medicinal Chemistry HR+, HER2– Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles
Current Cancer Drug Targets Why and How We Should Treat Elderly Patients with Hypertension?
Current Vascular Pharmacology Sevoflurane in Intraoperative and Postoperative Cardiac Surgery Patients. Our Experience in Intensive Care Unit with Sevoflurane Sedation
Current Pharmaceutical Design Review of Topiramate: An Antiepileptic for the Treatment of Alcohol Dependence
Current Drug Abuse Reviews Dipeptidyl Peptidase-4 Inhibition: Linking Chemical Properties to Clinical Safety
Current Medicinal Chemistry